797749-91-8

Upstream product

• 226398-50-1 tert-butyl 4-[(4-fluorophenyl)sulfonyl]piperidine-1-carboxylate 
• 797749-89-4 4-(4-bromophenylsulfonyl)-1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidine 
• 557-21-1 dicyanozinc 
• 400729-09-1 1-(2,4-difluorophenethyl)-4-((4-fluorophenyl)sulfonyl)piperidine 
• 797750-42-6 N-tert-butoxycarbonyl-4-fluoro-4-(4-fluorophenylsulfonyl)piperidine 
• 797750-51-7 4-fluoro-4-(4-fluorophenylsulfonyl)piperidine 
• 797749-90-7 1-[2-(2,4-difluorophenyl)ethyl]-4-fluoro-4-(4-fluorophenylsulfonyl)piperidine 
• 143-33-9 sodium cyanide 

Relevant academic research and scientific papers

4-Fluorosulfonylpiperidines: Selective 5-HT2A ligands for the treatment of insomnia

Incorporation of fluorine at the 4-position of an existing series of sulfonyl piperidine 5-HT2A antagonists gave compounds with increased selectivity over the IKr potassium channel. This work led to the identification of 3b, a compound that gave no increase in QTc in the anesthetized dog up to plasma levels as high as 148 μM. Furthermore, 3b has been shown to increase slow-wave sleep bout duration and to decrease the number of awakenings in rats, indicating the potential utility of 5-HT2A antagonists in the treatment of insomnia.

4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR

Compounds of formula (I): are selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of adverse conditions at the central nervous system, such as sleep disorders and schizophrenia.